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Abbreviations:  
 
CIT  cold ischaemia time 
D  diameter 
DCD  donation after cardiac death 
DGF  delayed graft function 
ECD  extended criteria donor 
FCD  functional capillary density 
HMP  hypothermic machine perfusion 
IR  ischaemia reperfusion 
mM  millimolar 
NHRP  normothermic ex-vivo renal haemo-reperfusion 
OPS   orthogonal polarization spectral imaging 
PFI  perfusion flow index 
PI  perfusion index 
RBC  red blood cell 
rsMD  rapid sampling microdialysis 
SCS  static cold storage 
TLN  thrombalexin 
UW  University of Wisconsin solution 
WIT  warm ischaemia time 
µm  micrometre 
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Abstract:  
Background: Hypothermic machine organ perfusion (HMP) offers opportunity to manipulate 
grafts with pharmacological agents prior to transplantation. Pretreating organs with novel 
cytotopic anti-coagulant peptides that localise to endothelial cell membranes could ameliorate 
microvascular thrombotic sequelae posttransplantation. We describe experiments testing 
Thrombalexin (TLN), a novel cell binding thrombin-inhibitor, using porcine and unused human 
kidneys in a series of ex-vivo normothermic haemo-reperfusion models.  
Methods: 38 porcine kidneys were utilised. Control kidneys underwent pretreatment via HMP 
with either unmodified perfusion solution (n=15) or solution with Inactive-TLN (absent 
anticoagulant effect, n=4). Test kidneys were perfused with TLN treated solution (n=19). All 
kidneys then underwent haemo-reperfusion. Two unused human kidneys underwent a similar 
protocol. 
Results: HMP pretreatment facilitated delivery and tethering of TLN in the organ 
microvasculature. Haemo-reperfusion challenge demonstrated improved perfusion in TLN-
treated kidneys compared to controls: 26.4% superior flow (30.6 vs.23.1 ml/min/100g,p=0.019) 
and 28.9% higher perfusion flow indices (0.43 vs.0.32 ml/min/100g/mmHg,p=0.049). 
Orthogonal polarisation spectral imaging demonstrated superior microvascular capillary 
perfusion in TLN-treated organs vs. controls (9.1 vs. 2.8pl/s/mm
2
,p=0.021). Rapid-sampling 
microdialysis for cortical [lactate] as a marker of tissue ischaemia/metabolism detected lower 
levels in TLN-treated kidneys. Perfusate analysis demonstrated reduced fibrin generation in 
TLN-treated kidneys correlating with perfusion data.  
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Conclusion: Our data suggest HMP graft pretreatment with cytotopic anticoagulants is feasible 
and ameliorates perfusion deficits seen in ex-vivo haemo-reperfusion models. There is potential 
for further development and application of this translational strategy to deliver locally-active 
anti-coagulants directly within grafts and decrease microvascular thrombotic sequelae, while 
avoiding systemic anticoagulation and its associated risks. 
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Introduction: 
'Organ painting' is a process of organ pretreatment prior to transplantation with therapeutic 
agents that are able to localise to the membranes of endothelial cells of the organ vasculature, 
'painting' the organ from the 'inside'.  
Such compounds can be termed 'cytotopic' [1] and such targeting has recently been applied in 
organ transplantation, with the design Mirococept (or APT070) a complement inhibitor molecule 
designed with cell binding functionality[2,3].  
Mirococept has been evaluated in animal models of limb-ischaemia, renal and cardiac 
transplantation to ameliorate both ischaemia reperfusion (IR) injury and rejection[4], and is 
currently undergoing MRC funded Phase 2 trials (EMPIRIKAL) in the UK in kidney 
transplantation.  
Serine plasma proteases of the coagulation cascade have been recently highlighted as potentially 
important and previously under-appreciated contributors in the pathogenesis of IR injury[5,6]. 
These developments indicate a complex interplay between endogenous coagulation and 
inflammatory processes, characterised by endothelial damage and generation and deposition of 
intravascular fibrin, propagation of which causes occlusion of the microvasculature, 
microcirculatory failure and the 'no re-flow' phenomenon[7,8]. In addition, overt renal allograft 
thrombosis occurs in 0.1-8.2% of renal allografts[9] and is a detrimental complication that is 
variably implicated in 7-44% of all cases of early graft loss in adults[10,11]. 
With the increasing use of ECD and DCD organs to address the growing need of patients on 
transplant waiting lists, the impact of IR injury is seen by the higher rates of DGF in these more 
susceptible organs and this impacts on the acceptability of their use by transplant surgeons [12]. 
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However use of the DCD/ECD cohort could expand the donor pool by 40%[13]. Interventions 
that can improve organ viability, and improve function in the peri-operative period during which 
IR injury is most dominant are potential strategies to better utilise these donor organs[14] 
Heparin has been used extensively in prevention of thrombosis in transplanted organs in 
particular kidney and pancreas allografts[15–17]  although the risk of bleeding is significant, and 
prevention of thrombosis not guaranteed[15] . Therefore, an ideal approach would be a cytotopic 
that localises within the vasculature of the allograft, exerting an anticoagulant (and thus anti-
inflammatory) effect locally at the site of the IR response rather than systemically. Manipulating 
an organ in such a targeted way might negate the need for systemic anti-coagulation and be 
potentially more effective. 
To this aim we have utilized a membrane-associated anticoagulant derived from a minimized 
form of hirudin, (a known thrombin inhibitor, and naturally occurring peptide in the salivary 
glands of Hirudo medicinalis leeches). The principle underlying this synthetic cell-tethered 
inhibitor (Thrombalexin, TLN)[18] is similar to the complement inhibitor Mirococept[4]. TLN 
binds the cell phospholipid bilayer through a bis-myristoyl hydrophobic structure and a lysine-
rich sequence[19], and like hirudin TLN interacts with thrombin at the active site and at the 
fibrinogen-binding exosite I[20]. 
Here in we describe a series of experiments, building on our experience[21] with hypothermic 
machine perfusion (HMP) to evaluate the potential of ex-vivo organ pretreatment with TLN in 
ameliorating microvascular coagulation and both macro and micro vascular perfusion deficits in 
a series of normothermic ex-vivo renal haemo-reperfusion (NHRP) circuits. These experiments 
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utilised both porcine kidneys, and unused human kidney grafts allocated by NHS Blood and 
Transplant for research.  
 
Methods:  
Experiments 
Four experiments were conducted and compared TLN to controls. Experiments 1-3 involved 
porcine kidneys. Experiment 2 incorporated additional assessment of porcine kidneys during 
NHRP, specifically orthagonal polarisation spectral (OPS) imaging, and rapid sampling 
microdialysis (rsMD). Experiment 4 involved use of human kidney grafts allocated for use in 
this research.  
Details of the experimental groups and the protocols used are summarised in Figure 1. All 
experiments were conducted in laboratories of the Department of Surgery at Imperial College 
London in collaboration with MRC Centre for Transplantation at King's College London. 
Organ Retrieval and Hypothermic Machine Perfusion (HMP) 
Kidneys were retrieved from landrace pigs terminated at a local abattoir by stunning and 
exsanguination. This model of sacrifice was akin to substantial head injury and also DCD as 
animals were only accessed once cardiac death had occurred. There was a target warm ischaemia 
of approximately 15 minutes until the institution of cold flush. Access was achieved through a 
midline laparotomy incision, kidneys were retrieved via en-block dissection, flushed with 
preservation solution (500-1000ml at 100cmH20) and packed on ice for transport to the 
laboratory. Paired kidneys were matched between treatment and control groups. Static cold 
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storage time prior to HMP including transportation was on average 5 hours. All kidneys were 
perfused initially on a Waters Medical Systems RM3 device for 4 hours of HMP stabilization 
with UW solution according to clinical protocols[22].  
Human allografts 
Approval was granted for research use of human kidney grafts initially retrieved but 
subsequently not used for transplantation by a National Research Ethics Committee (IRAS 
code:84202) and NHS Blood and Transplant (the national regulator of organ transplantation in 
the United Kingdom). One pair of organs were used in this study as part of a direct preclinical 
model in experiment 4, and underwent identical perfusion protocols as porcine kidneys. 
Cytotopic Anti-coagulant 
TLN is a conjugate peptide of the direct thrombin inhibitor  [D-Phe-L-Pro-L-Arg-L-Pro-Gly-
Gly-Gly-L-Asp-Gly-L-Asp-L-Phe-L-Glu-L-Glu-L-Ile–L-Pro-L-Glu-L-Glu-L-Tyr-L-Leu-Gly-
Gly-L-Cys-amide] and the cytotopic-tail APT3146  [(N-alpha,-N-epsilon-Bis-myristoyl-Lys-Ser-
Ser-Lys-Seryl-Pro-Lys-Lys-Asp-Asp-Lys-Lys-Pro-Gly-Asp-(S-2-pyridyldithio) Cys][19]. The 
peptide had a mass of 4649 Daltons as determined by time-of-flight mass spectrometry and was 
prepared by reaction of the 2 components in aqueous solution followed by further 
purification[18]. A fluorescently labelled-version, lacking anticoagulant activity (FAM-PTL), 
was used to study localisation of TLN within the kidney. The component peptides were prepared 
using solid phase synthesis by Cambridge Research Biochemicals, Billingham, UK and the 
conjugate also synthesized at scale by Almac Sciences, Craigavon, UK.  
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TLN Pretreatment 
After HMP stabilization, kidneys underwent pretreatment with TLN. This consisted of 3 distinct 
30 minutes hypothermic perfusion episodes (diagrams summarising this protocol and 
experimental groups can been seen in Figure 1). A translational HMP setting was chosen to 
facilitate delivery of TLN into grafts mimicking what would potentially occur in clinical 
practice.  
1) Washout-1: 30 minutes HMP with fresh perfusate to limit the amount of remaining donor 
blood in the organ and perfusate from the initial 4 hours of HMP;  
2) Treatment: perfusion with perfusate containing anticoagulantly active-TLN (Protein Test 
Groups 1-4; PTG1-4); or as controls, either un-modified perfusate (Control Groups 1, 2 and 4; 
CG1, CG2, CG4) or perfusate with anticoagulantly inert „tail-only‟ proteins (Tail Control Group 
4, TCG4); and  
3) Washout-2: 30 minutes HMP with fresh perfusate to facilitate removal of non-adherent TLN 
from the organ vasculature. 
To provide for an ideal control environment 1 kidney from each pair underwent 'treatment' with 
TLN while the other served as 'untreated' control.  
Normothermic Haemo-reperfusion 
Kidneys underwent 6 hours of normothermic haemo-reperfusion (NHRP) using minimally anti-
coagulated whole blood (WB) perfusate (10,000U/L Heparin); 600mls, 3:1 ratio WB:0.9% 
saline. RM3 units were setup to facilitate NHRP (see Figure 1). Human grafts were also perfused 
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with porcine whole blood to establish the effect of TLN treatment in a haemo-reperfusion model. 
This phase of reperfusion mimics the injury suffered in vivo. 
OPS Imaging 
OPS (Cytometrics, Inc.; Philadelphia, USA) was used to assess the microcirculation[23]. OPS is 
based on cross-polarisation of reflected green (548nm) light by oxy- and deoxy-hemoglobin in 
RBCs, enabling blood vessels to be visualized and assessed for perfusion metrics including 
capillary diameter (D), functional capillary density (FCD), RBC velocity (RBCv), with a 
perfusion index (PI) calculated [24]. See Supplementary Information, SDC, 
http://links.lww.com/TP/B337. 
rsMD 
A novel in-house rsMD system previously described [25] for in-vivo assessment of tissue 
biochemistry and metabolism was used to evaluate renal tissue biochemistry during HMP 
stabilization and NHRP. Lactate levels were analysed in real-time (every 60s). Through 
microdialysis probes (MAB11.35.4, Microbiotech, Sweden) inserted superficially into the 
parenchyma of the lateral cortex, lactate levels were analysed in real-time (every 60s).  
Clotting Assays 
Perfusate samples during pretreatment were assessed via a simple calcium chloride/human 
plasma clotting assay. Blood perfusate samples during NHRP were collected and analysed for 
levels of fibrin degradation products (INNOVANCE® D-Dimer Siemens Healthcare 
Diagnostics), fibrinogen and Prothrombin Factor 1+2 (Quadratech Diagnositics Ltd, UK) using 
commercially available kits. 
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Histology 
Wedge biopsies were taken for histopathological analysis after 6hours of NHRP for routine 
staining. Frozen sections were used for immuno-histochemistry for fibrin(ogen) (No. 350, 
American Diagnostica Inc). Samples were evaluated using a scale of 0-4 for endothelial 
detachment, presence of tubular debris/tubular intratubular cell detachment, tubular dilatation, 
and peritubular vessel congestion according to the degree of changes seen in each field of view at 
10x magnification.  
TLN Adherence 
Two porcine kidneys and 1 human kidney were treated with a TLN-tail derivatised at the N-
terminus with a FAM fluorescent derivative (FAM-PTL) to histologically demonstrate tethering 
and adherence to the kidney microvasculature.  
Statistics 
Values are represented as mean and standard deviation. Continuous variables were plotted as the 
mean area under the curve and evaluated using the paired students T-test or Wilcoxon signed 
rank test, and repeated measures analysed using ANOVA for repeated measures with Bonferroni 
correction, as required. Data and statistical analysis was performed using Microsoft® Excel 
Software (Reading, UK). P value of ≤0.05 was considered significant. 
Results: 
Kidney Characteristics 
Thirty-eight porcine kidneys and 2 human kidney grafts were utilized and Table 1 summarises 
porcine kidney characteristics in the experimental groups.  
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Hypothermic Machine Perfusion Stabilization 
Perfusion characteristics and weight gain in kidneys during initial HMP stabilization were 
similar between the Protein Treated Groups (PTG1,PTG2,PTG3) and the Control Groups (CG1, 
CG2, TCG3), and are summarised in Table 2. 
TLN Delivery and Adherence during pretreatment phase  
Perfusate samples taken during the „treatment‟ phase of organ pretreatment from TLN treated 
kidneys (PTG1, PTG2 and PTG3 Groups) were assessed using a simple clotting assay that 
indirectly measured the concentration of TLN in the perfusion fluid. These data are shown in 
Figure 2.  A higher clotting ratio indicates a greater concentration of TLN present in the sample. 
In all experiments, the concentration of TLN fell during the treatment phase, consistent with 
uptake in the kidney.  During the washout-2 phase, clotting ratios increased, consistent with 
washout of non-adherent TLN. 
Adherence of TLN  
Porcine and human grafts treated with FAM-PTL histologically confirmed tethering and 
adherence to kidney microvasculature after pretreatment, with continued adherence after 6 hours 
of NHRP (Figure 3).  
NHRP 
TLN treated kidney groups demonstrated superior blood flow and PFI compared to the Control 
Group kidneys (Figure 4). Renal blood flow rates were on average 26.4%, 31.7%, and 45% 
higher, and PFIs 28.9%, 25.1%, and 42.5% greater in protein treated PTG1, PTG2 and PTG3 
kidneys compared to controls.  
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Orthogonal Polarisation Spectral Imaging 
In Experiment 2 OPS data was recorded and analysed for 4 pairs of kidneys after 6 hours NHRP 
to assess the microdynamics of the kidney microvasculature. FCD was similar between treated 
and non treated kidneys however TLN treated kidneys had 44% larger diameter capillaries, 50% 
faster RBCv, 3.5 times greater CBFs and PIs compared to the nontreated control kidneys (Figure 
5).  
 
Rapid Sampling Microdialysis  
Data of cortical micro-dialysis levels were recorded for 4 pairs of kidneys during Experiment 2 
during the HMP stabilization phase, and NHRP. During HMP cortical microdialysis lactate 
concentrations were similar between the nontreated control and TLN-treated kidneys (CG2: 
0.128 ±0.006 mM/min vs. PTG2: 0.137 ±0.04 mM/min, p=0.783). In NHRP cortical lactate 
levels were higher in non-treated vs. TLN-treated kidneys (CG2: 3.28 ±1.04 mM/min vs. PTG2: 
1.67 ±0.28 mM/min, p=0.072), with the difference approaching significance (Figure 6). 
NHRP Coagulation Analysis 
Coagulation data is summarised in Table 2. Higher levels of D-Dimers (average AUC) were 
observed over the 6 hours of perfusion in the Experiment 1 control group, CG1 (14.5 ±7.9 mg/L 
) vs. the TLN-treated kidneys, PTG1 (9.5 ±5.1 mg/L, p=0.051) with this difference at verge of 
significance. No other differences were observed in coagulation parameters between TLN-
treated and nontreated kidneys in Experiments 2 and 3. 
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Histology 
Light microscopy histological assessment of biopsy samples between Control (CG1-2, TCG3) 
and TLN-treatment (PTG1-3) Groups showed no significant differences in endothelial 
detachment, tubular debris/epithelial detachment, tubular Dilatation, and peritubular congestion, 
all p-values >0.5. Immuno-histochemistry for fibrin(ogen) demonstrated a generalised 
fibrin(ogen) deposition in interstitial tissues and peritubular capillaries, with no difference 
between treated and nontreated kidney grafts. 
Pre-clinical Experimentation with Human Kidney Grafts 
A pair of DCD kidney grafts were used in a preclinical model in Experiment 4. CIT was 78 
hours (4680 minutes) until start of the experiment. Table 3 summarizes kidney characteristics, 
perfusion dynamics, perfusate clotting results and microdialysis cortical lactate levels in these 
kidneys. During HMP stabilization perfusion characteristics were superior in the CG4 control 
kidney vs. the PTG4 kidney. 
During NHRP despite similar systolic perfusion pressures (CG4: 73.2mmHg vs. PTG4: 
72.9mmHg) TLN treated kidneys demonstrated better perfusion with 17%% higher renal blood 
flow and perfusion indices. Renal blood flow in the PTG4 group was 70.8 ml/min/100g vs. CG4: 
60.7 ml/min/100g, and PFI: in PTG4: 0.97 ml/min/100g/mmHg vs. CG4: 0.83 
ml/min/100g/mmHg. Micro-dialysis lactate concentrations were lower in the control kidney 
during HMP prior to treatment but were subsequently 36% lower in the treated PTG4 kidney 
during NRHP. D-Dimer and fibrinogen levels were 2.5-3x higher over the 6 hours of perfusion 
in the control CG4 group. Percent weight changes, and  reperfusion injury demonstrated by light 
microscopy were similar.  
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Discussion: 
The increasing use of ECD and DCD organs to expand donor pools means any approach that 
could ameliorate micro-vascular dysfunction and improve organ perfusion at the reperfusion 
stage is in high clinical demand. TLN is a novel membrane localising 'cytotopic' anti-coagulant 
construct that has proven efficacy in improving graft function in murine kidney transplantation 
models[26]. This is the first study of the pretreatment of large animal organs with this cytotopic 
anti-coagulant agent using HMP as a delivery vehicle, and further assessing the benefits of this 
pre-treatment using a NHRP challenge. Using a series of translational porcine ex-vivo renal 
perfusion and haemo-reperfusion models we demonstrated HMP can be used to deliver TLN into 
the vasculature of a kidney graft, and facilitates cytotopic tethering and adherence; improving 
macro and micro-vascular organ tissue perfusion, with evidence of its anticoagulant activity 
during NHRP challenge.  
HMP successfully delivered TLN into the kidney vasculature, with tethering and adherence. The 
decrease in clotting time ratios using the simple plasma-CaCl based clotting assay in samples 
from Experiment 1 taken as the treatment phase progressed demonstrates removal of TLN from 
the perfusate and sequestration onto the vasculature, while at the same time demonstrating 
functionality of the HLL anti-coagulant moieties. Similar trends were seen Experiment 2 and 3 
demonstrating removal of TLN from the perfusate. Cytotopic protein adherence in these 
experiments was confirmed using the FAM-PTL analogue. This qualitatively demonstrated the 
presence of the TLN after treatment, with continued adherence to the kidney microvasculature 
and ultra-structure after 6 hours of NHRP challenge when using the perfusion protocols in these 
experiments. Furthermore allied work in rodent models the effective residence time of TLN is 
approximately 24 hours (unpublished data). The translational approach using hypothermic 
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delivery of TLN into grafts mimics the potential strategy that could be employed clinically in 
organ preservation where HMP is increasingly becoming common-place versus simple cold 
storage. With the recent advent of normothermic perfusion preservation, as this new technology 
develops into wider use in clinical practice both in the UK and international settings there is 
increasing potential for the feasible delivery of localising agents in a more physiological and 
normothermic environment, and this is an area of ongoing research at our institution.   
Isolated organ reperfusion circuits using autologous blood have developed as ex-vivo methods to 
experimentally assess organ viability in large animal models without the need for live auto-
transplantation[27]. The normothermic haemo-reperfusion phase of the protocol used minimally 
heparinised autologous whole porcine blood. The aim of the NHRP protocol was to induce a 
haemodynamic procoagulant insult to the kidney to allow study of the impact of the presence of 
the TLN tethered to the kidney endothelium. Induction of clotting was demonstrated indirectly 
by the detection of increasing D-Dimers levels as  reperfusion progressed (data not shown), and 
was especially marked in the control kidneys, indicating progressive fibrinolysis. This was 
associated with histological evidence of tubular and endothelial damage, and a generalised and 
diffuse pattern of fibrin(ogen) deposition, which is characteristic of IR injury[28].     
Immediately after transplantation there is systemic activation of the coagulation system[29]. The 
subsequent complex interface between coagulation and inflammation mediates reperfusion 
damage to the endothelium, and subsequent microcirculatory failure. This provokes further 
ischaemia and tissue injury manifested as DGF, with a higher risk of immunologic 
rejection[30].The impact of thrombin inhibition has been recently demonstrated in a porcine 
kidney autotransplantation model of DGF, as a direct thrombin inhibitor (melagatran) improved 
autograft function and survival when added either to UW during static cold-storage or 
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administered systemically[31] . Because thrombin has both procoagulant and inflammatory 
effects, thrombin inhibition can ameliorate both these sequelae. 
Our experiments suggest that TLN anchored to the endothelium can inhibit the activation of 
clotting. This resulted in superior macro-vascular and micro-vascular perfusion metrics (renal 
blood flow, PFI) in TLN-treated kidneys compared to the nontreated and Tail-only protein 
treated controls. Macro-vascular PFI is a useful calculation as it incorporates both renal flow 
rates and systolic pressure but corrects for differences in kidney mass. In these experiments 
observed renal blood flow rates and PFIs were between 25-45% superior in the TLN-treated 
kidneys vs. controls. Relative flow rates during ex-vivo NHRP can be considered indicators of 
relative organ viability[32].  
Ameliorating the microcirculatory perfusion dysfunction that is seen in renal IR injury in both 
experimental and clinical settings has been shown to be important and beneficial in improving 
initial graft function after transplantation, and limiting DGF[33–35].  
OPS of the microcirculation demonstrated better perfusion in TLN-treated kidneys during the 
NHRP challenge. The improved calculated microvascular PI (pl/s/mm2) in these kidneys 
stemmed from larger diameter cortical capillaries, and faster blood flow through these vessels.  
The presence of larger calibre vessels can be due to relative vessel dilation[36] secondary to 
potentially less thrombin action at the endothelial cell surface, and less generation of local 
vasoconstrictors[37] (eg endothelin) or alternatively more release of nitric oxide (NO). 
Alternatively the larger capillaries could be due to less fibrin formation and aggregation of 
cellular blood components at the endothelial surfaces, rendering better transit through 
vessels[24]. The larger observed diameter in these vessels may relate to a relative inhibition of 
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dynamic leucocyte aggregation at the endothelial due to less thrombin mediated inflammatory 
activation, and diminished fibrin generation. Fibrin it-self is known to be a potent 
proinflammatory mediator[38]. 
These changes correlated with the trend for reduced D-Dimer levels during NHRP challenge in 
TLN-treated kidneys. Although our data approached significance in only 1 experiment this may 
have been due to confounding effects of the sacrifice used in this uncontrolled DCD model 
(where a cytokine surge from stunning may render blood more procoagulant), and where D-
Dimers levels are only an indirect measure of thrombin activity.    
Faster RBC velocity could be attributed to the relatively lower intravascular clotting activity and 
less obstruction to flow in capillaries. Maintaining equal systolic perfusion pressures between 
control and TLN-treated kidneys during NHRP dictates that any observed differences in renal 
perfusion blood flow dynamics (blood flow rates, PFI) are due to inherent differences in the 
kidney vasculature and effect of the presence of the cytotopic anti-coagulant proteins. The 
similar changes in weight in kidneys during HMP and NHRP further indicates that perfusion 
differences between treated and nontreated grafts are not due to tissue oedema limiting blood 
flow. 
These changes in microcirulatory parameters also associated with lower levels of tissue lactate 
detected via rsMD in TLN-treated kidneys, most likely reflecting better overall tissue perfusion, 
both in relative oxygen delivery, and potentially washout of toxic metabolites[39,40]. The higher 
variability seen in the control group reflects the variation in graft damage sustained during 
sacrifice and retrieval, and is an inherent component of an uncontrolled DCD model and may be 
a reason for the lack of statistical significance.  
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Furthermore rsMD analysis was available only for 4 pairs of kidneys due to technical difficulties 
with the rsMD system itself. Localization of the rsMD probes to the cortex was done visually 
without image guided confirmation introducing the possibility of placement of part of the probe 
in an alternate region of the kidney parenchyma  with differing metabolic profiles to the 
cortex[25]. 
These data complement those obtained in other model systems illustrating the benefits of 
localised anticoagulation. Inhibition of thrombin in hearts of transgenic mice[41] was associated 
with complete resistance to acute humoral rejection[42] in a highly stringent xenogeneic model.  
Similarly, building on the work of Ding et al[43], Crikis et al reported improved graft survival of 
transgenic hearts from mice expressing human thrombomodulin localised to endothelium[44]. In 
the same study these transgenic mice demonstrated a reduced inflammatory response in stasis-
induced thrombosis and a mouse-to-rat xenograft model, with reduced HMGB1 levels in LPS 
induced endoxtaemia. These reports demonstrate the translational potential of targeting 
anticoagulants to graft endothelial cells and to inhibit coagulation and inflammation.  
Use of appropriate preclinical models is a prerequisite to the development of protocols for 
clinical introduction. The data obtained from TLN preconditioned human kidneys correlated with 
our findings in the porcine models. These experiments utilized porcine blood during the NHRP 
challenge phase, and as evidenced by the progressive increase in fibrin degradation products 
during NHRP in the control kidneys this combination generated ideal conditions under which the 
impact of TLN could be studied.   
The cytotopic approach suggested here using HMP to deliver TLN is novel and theoretically 
ideal. An allograft  could undergo HMP at the recipient transplant centre, where TLN would be 
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added to the perfusate, to facilitate tethering and pretreat the endothelium. The allograft would 
ultimately be transplanted with the thrombin inhibiting anti-coagulants localised to the allograft 
vasculature, limiting the need for systemic anti-coagulation (with associated bleeding risks) and 
be potentially more effective. The thrombin inhibiting effects of the TLN would ideally reduce 
both the procoagulant and proinflammatory actions of thrombin - ameliorating IR responses, and 
improve postoperative allograft perfusion and function. 
Cytotopic painting of the endothelium with TLN can be considered a potential example of 
'immunocamouflage' where by the cell membrane surface is modified by nonimmunologic 
molecules creating a barrier[45]. Although the definitive mechanism of the effect of TLN in this 
model has not been demonstrated here, it is most likely through inhibition of thrombin by the 
hirulog sequence contained within; this would be consistent with all in-vitro and ex-vivo testing 
performed on TLN so far. However, we cannot completely rule out a direct effect due to 
interaction with the glycocalyx and other membrane associated proteins.   
The other caveat to be applied to interpreting this work is that the histological outcomes did not 
reveal remarkable differences in the treated grafts, and this is likely due to the experimental time 
frame employed. Despite use of isolated organ reperfusion circuits as well established initial 
alternatives to in-vivo experimentation the relatively short duration of ex-vivo reperfusion is not 
a sufficient timescale for development of histological changes that can be seen in-vivo during 
transplantation[46] with the predominant effects of reperfusion in this model on cellular and 
molecular processes within the graft. Extending experimentation and reperfusion time would 
allow further development of histological sequale and the use of  a large animal porcine auto-
transplant model would also allow for functional graft assessment. 
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Conclusion: 
For the first time the pretreatment of kidney grafts with cytotopic therapeutics using HMP, in ex-
vivo porcine and preclinical human kidney perfusion models has been successfully 
demonstrated, and  the presence of these agents improves organ perfusion. There is a high 
potential for application of this cytotopic technique to clinical practice, not solely for kidney 
transplantation, but for also for other organs, for example pretreating marginal pancreatic 
allografts which are very susceptible to reperfusion injury and subsequent allograft thrombosis. 
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Figure/Table Legends: 
Figure 1 Schematic summary of experimental protocols for TLN testing in porcine 
and human renal grafts illustrating the 3 distinct phases: HMP stabilization, TLN 
treatment and Normothermic haemo-reperfusion. Experiments 1 and 2 were 
consecutive experiments with similar perfusion protocols and the addition of rsMD 
and cytoscan assessment of grafts during reperfusion. A photograph of the 
normothermic haemoreperfusion reperfusion circuits using modified Waters Medical 
RM3 perfusion device is shown. SCS: static cold storage, HMP: hypothermic machine 
perfusion, CG: Control Group, PTG: Protein Test Group, UW: University of 
Wisconsin Solution. 
 
Figure 2. Perfusate Clotting Analysis. This method was used as an indirect analysis 
of the amount of TLN present in the perfusion fluid. Clotting times are expressed as 
multiple of the clotting time for a control sample of unaltered perfusate (represented 
by the blue line). The larger the value the greater the concentration of TLN present.  
Experiment 1: ANOVA p=0.001, 0 mins (2.19 ± 0.17) vs. 15 mins (1.89 ± 0.12) 
p=0.001, 30mins (1.92 ±0.11) vs. start washout (1.15 ± 0.04)p<0.001, start vs. end of 
washout (1.26 ± 0.1) NS, 30mins vs. end of washout p<0.001. Experiment 2: ANOVA 
p=0.001, Clotting time ratios trended lower during treatment: 0 mins (2.0 ± 0.09), 15 
mins (1.97 ± 0.11), 30mins (1.89 ±0.14), p>0.05 for all treatment comparison. Start 
of washout (1.15 ± 0.02) vs. end of washout (1.46 ± 0.06 ) p=0.001 and 30mins vs. 
both start of washout and end of washout p=0.001, p=0.002 respectively. Experiment 
3:  ANOVA p=0.004, Clotting time ratios trended lower during treatment: 0 mins 
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(1.72 ± 0.06), 15 mins (1.5 ± 0.02), 30mins (1.51 ±0.02), p>0.05 for all treatment 
comparisons. There was no difference between the start of washout (1.12 ± 0.03) vs. 
end of washout (1.15 ± 0.01 ) p=0.741 and 30mins vs. both start of washout and end 
of washout p=0.062, p=0.086 respectively.  
 
Figure 3. TOP - Histology of biopsies taken from a porcine kidney during 
experimental treatment with fluorescent labelled (FAM-PTL) tail molecules. Prior to 
treatment (A); after treatment demonstrating presence of the proteins adherent to the 
kidney microvasculature (B); and with continued adherence after 6 hours of 
normothermic reperfusion with blood (C). BOTTOM - Histology of biopsies from a 
human kidney as part of experiment 5. Prior to treatment with fluorescent labelled 
(FAM-PTL) tail molecules (D); after treatment with FAM-PTL demonstrating 
presence of the proteins adherent to the kidney microvasculature (E); and with 
continued adherence after the further 30 minutes of Washout-2 perfusion (F). 
 
Figure 4. NHRP renal perfusion dynamics in experiments 1-3. Protein Test Group 
kidneys demonstrated higher renal blood flow rates (PTG1: 30.6 ± 6.8, PTG2: 27.1 ± 
9.4, PTG3: 25.9 ± 8.6  ml/min/100g) than control kidneys (CG1: 23.1 ± 3.7, CG2: 
20.6 ± 7.6, TCG3: 17.9 ± 6.2 ml/min/100g; p=0.019, p=0.022, p=0.009 respectively), 
as well as higher perfusion flow indices PTG1: 0.43 ± 0.12, PTG2: 0.54 ± 0.22, 
PTG3: 0.49 ± 0.16  ml/min/100g/mmHg) vs. control kidneys (CG1: 0.32 ± 0.1, CG2: 
0.44 ± 0.22, TCG3: 0.34 ± 0.12 ml/min/100g/mmHg; p=0.049, p=0.031, p=0.009 
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respectively) during 6 hours of NHRP challenge. Two-tailed paired t-test. 
*=significant difference vs. corresponding control group. 
 
Figure 5. Example of postcapture frame analysis (TOP LEFT) of a kidney undergoing 
OPS assessment (TOP RIGHT) and OPS microcirculatory perfusion dynamics in 
kidneys at 6 hours of NHRP (charts). Functional capillary density was similar 
between treated and non treated kidneys (CG2: 19.3 ± 3.1 % vs. PTG2: 20.5 ± 2.0 %, 
p=0.402). TLN treated kidneys recorded vessel diameters were larger (CG2: 7.44 ± 
0.81 µm vs. PTG2: 10.77 ± 1.23 µm, p=0.052), and RBC velocity (CG2: 272.1  ± 
26.3 µm/s vs. PTG2: 403.2 ± 31.2 µm/s, p=0.011), calculated CBF (CG2: 13.2 ± 3.65 
µm3/s vs. PTG2: 41.9 ± 14.5 µm3/s, p=0.032), and the PI (CG2: 2.77  ± 0.98 
pl/s/mm
2
 vs. PTG2: 9.05 ± 2.48 pl/s/mm
2
, p=0.021) higher compared to control 
kidneys. The HI calculation revealed similar levels of homogenous perfusion within 
the areas sampled within each kidney (CG2: 3.21 ± 0.18 AU vs. PTG2: 3.27 ± 0.21 
AU, p=0.791). Two-tailed paired t-test. *=significant difference vs. control group. 
 
Figure 6. rsMD: Scatter diagram of rsMD readings measured from 1 porcine kidney 
during HMP and NHRP (Top). NHRP cortical lactate concentrations trended higher in 
non-treated vs. treated kidneys during (CG2: 3.28 ± 1.04 mM/min vs. PTG2: 1.67 ± 
0.28 mM/min, p=0.072, bottom left). Photograph of kidney undergoing microdialysis 
monitoring by insertion of probes into cortex (bottom right). 
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Table 1. Porcine kidney characteristics. 
 
Table 2. HMP perfusion dynamics, NHRP blood perfusate clotting analysis, and 
percent weight change in kidneys during HMP and NHRP in Treatment and Control 
Groups for Experiments 1-3 are illustrated. * Higher levels of D-dimers were 
observed in control CG1 (14.5 ± 7.9 mg/L ) vs. the treated kidneys, PTG1 (9.5 ± 5.1 
mg/L, p=0.051). Two-tailed paired t-test. 
 
 
Table 3. Results from Experiment 4: Human kidney graft characteristics, HMP 
dynamics, weight changes, rsMD levels during NHRP, and NHRP blood perfusate 
clotting data. There was insufficient sample for PF1.2 testing. 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Tables:    
Table 1 
Kidney 
Characteristics 
Warm Ischaemia Time  
(minutes) prior to  
start of SCS 
SCS Cold Ischaemia 
Time Before HMP 
(minutes) 
Weight Pre-HMP (g) 
Overall for  
All Kidneys 
(n=36) 
15  ( 10-20) 298  ( 219-480) 233 (107-330) 
       
Experiment 1  CG1 PTG1 CG1 PTG1 CG1 PTG1 
 
13.6 (2.4) 12.8 (2.6) 345 (80.6) 348 (80.9) 175.1 (229-
116) 
185.7 (258-
107) 
Experiment 2  CG2 PTG2 CG2 PTG2 CG2 PTG2 
 
16 (2) 16 (2) 334 (76) 334 (76) 253 (188-330) 237 (197-315) 
Experiment 3 TCG3 PTG3 TCG3 PTG3 TCG3 PTG3 
 15.5 (0.6) 15.5 (0.6) 247 (16) 247 (16) 257 (249-295) 251 (240-290) 
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Table 2 
HMP  Perfusion 
Dynamics 
Systolic Pressure (mmHg) 
Perfusate Flow Rate 
(ml/min/100g) 
Perfusion Flow Index 
(ml/min/100g/mmHg) 
Experiment 1 CG1 PTG1 CG1 PTG1 CG1 PTG1 
 46.2 ± 9.4 43.5 ± 6.3 21.4 ± 6.7 23.4 ± 8.2 0.55 ± 0.22 0.52 ± 0.17 
Experiment 2 CG2 PTG2 CG2 PTG2 CG2 PTG2 
 38.7 ± 3.8 38.3 ± 3.8 16.2 ± 6.2 16 ± 5.8 0.42 ± 0.08 0.39 ± 0.12 
Experiment 3 TCG3 PTG3 TCG3 PTG3 TCG3 PTG3 
 36.8 ± 2.7 36.8 ± 1 12.7 ± 3.8 13.6 ± 4.2 0.38 ± 0.08 0.37 ± 0.13 
 
NHRP Perfusate  
Clotting Analysis 
D-dimers (mg/L) Fibrinogen (µg/L) 
Prothrombin Fragment 1+2 
(mg/L ) 
Experiment 1 CG1* PTG1 CG1 PTG1 CG1 PTG1 
 
14.5 
 ± 7.9 
9.5 
 ± 5.1  
0.385  
± 0.06  
0.373  
± 0.21 
0.006  
± 0.003  
0.007 
± 0.002  
Experiment 2 CG2 PTG2 CG2 PTG2 CG2 PTG2 
 
5.63  
± 2.2  
11.2  
± 11.06  
1.08  
± 0.19  
1.2  
± 0.24 
0.005  
± 0.001  
0.009  
± 0.002  
Experiment 3 TCG3 PTG3 TCG3 PTG3 TCG3 PTG3 
 
6.18  
± 9.6  
6.4 
 ± 7  
0.78  
± 0.07  
0.79  
± 0.33  
0.002  
± 0.001  
0.001 
± 0.002  
 
 Percent Weight Change Post HMP (%) Percent Weight Change Post NHRP (%) 
Experiment 1 CG1 PTG1 CG1 PTG1 
 42.5  ±  12.6 42.8  ±  12.9 10.9 ± 7.8 11.9 ± 9.4 
Experiment 2 CG2 PTG2 CG2 PTG2 
 
20.6 ± 7.8 21.8 ± 7.2 9.8 ± 7.9 14.2 ± 14.8 
Experiment 3 TCG3 PTG3 TCG3 PTG3 
 14.8 ± 5.5 14 ± 5.5 19 ± 10 27.8 ± 4.4 
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Table 3 
Kidney  
Characteristics 
Warm Ischaemia Time (minutes) 
Cold Ischaemia Time 
Before HMP (minutes) 
Weight Pre-HMP (g) 
Experiment 4 CG4 PTG4 CG4 PTG4 CG4 PTG4 
 NA NA 78 hours 78 hours 210 230 
    
HMP Stabilization 
Perfusion  
Dynamics 
Systolic Pressure (mmHg) 
Flow  
Rate (ml/min/100g) 
Perfusion Flow Index 
(ml/min/100g/mmHg) 
Experiment 4 CG4 PTG4 CG4 PTG4 CG4 PTG4 
 37.8  49.5  18.2  10.2  0.48  0.2  
     
Weight Changes 
Percent Weight Change 
Post HMP (%) 
Percent Weight Change 
Post NHRP (%) 
  
Experiment 4 CG4 PTG4 CG4 PTG4   
 14.3 15.6 1.2 -0.8   
     
RSMD [Lactate] HMP [Lactate] mM/min 
NHRP [Lactate]    
mM/min 
  
Experiment 4 CG4 PTG4 CG4 PTG4   
 0.17 0.28 6.997 4.442   
    
Perfusate  
Analysis 
Ddimers (mg/L) Fibrinogen (µg/L) 
 
Pro-thrombin Fragment 1+2 
(mg/L ) 
Experiment 4 CG4 PTG4 CG4 PTG4 CG4 PTG4 
 4.74 1.89 3.7 1.2 NA NA 
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Methods: 
Orthogonal Polarization Spectral (OPS) Imaging 
OPS has been validated in animal [1–5] and human models  [6,7] and has been used to 
investigate changes in the microcirculation in transplantation settings [8–11]. Images were 
recorded for ≥2 areas after 6 hours of NHRP in 4 pairs of kidneys. Analysis and quantification of 
microdynamic parameters was performed offline by frame-to-frame analysis of the recorded 
images using a computer-assisted image analysis system (CapiScope, KKTechnology, United 
Kingdom). Analysis included a quantitative assessment of capillary diameters (D), functional 
capillary density (FCD) and RBC velocity (RBCv). In each sample diagnostic fields (region of 
interest) each measuring 782x782 µm (0.611 mm
2
) of interest that were isolated and analysed. 
FCD was defined as the ratio of area of RBC perfused capillaries per area of observation (mm
2
), 
directly reflecting the state of nutritive tissue perfusion[12]. vRBC (µm/s) was measured in the 
midpoint of ten capillaries that crossed a designated grid within the ROI by means of frame-to-
frame analysis (Modification of De Backer's score)[13]. Individual volumetric capillary blood 
flow (CBF; pl/s) was calculated from RBCv and D metrics according to the formula vCBF = 
∏(D/2) x vRBC . To evaluate changes in overall capillary perfusion, a perfusion index (PI) was 
calculated from using the FCD and CBF metrics (PI = FCD x CBF, pl/s/mm
2
). The degree of 
homogeneity (heterogeneity index, HI) in CBF was assessed by expressing the standard 
deviation (SD) relative to the difference between the maximum and minimum of the CBF 
(obtained from all observations from 1 experiment at the time point). 
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